Skip to search formSkip to main contentSkip to account menu

sorafenib

Known as: 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, SFN 
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologySorafenib:MCnc:Pt:Ser/Plas:Qnanalogs & derivativessorafenib 200 MG Oral Tablet [Nexavar]

Narrower (1)

Nexavar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials
Review
2012
Review
2012
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Highly Cited
2012
Highly Cited
2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Review
2011
Review
2011
An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.
Highly Cited
2010
Highly Cited
2010
Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving…
Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma (mRCC), and contrast… 
Highly Cited
2010
Highly Cited
2010
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials
There is no effective systemic therapy for patients with advanced hepatocellular carcinoma (HCC) except liver transplantation… 
Review
2009
Review
2009
Novel treatments for hepatocellular cancer.
Review
2007
Review
2007
Sorafenib: delivering a targeted drug to the right targets
Approved for the treatment of advanced renal cell carcinoma by the US FDA and other regulatory agencies, sorafenib is an agent… 
Highly Cited
2007
Highly Cited
2007
Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Purpose: Interactions between the multikinase inhibitor sorafenib (Bay 43-9006) and the histone deacetylase inhibitor vorinostat… 
Highly Cited
2006
Highly Cited
2006
Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells
Mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) are activated in the majority of gliomas and contribute to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)